Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 4/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.35 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.33 |
| ▸ | SHBG | P04278 | 2/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 2/20 | 0.31 |
| ▸ | PGR | P06401 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11757678 | 0.85 | TLR4 (0.50) | TLR4CYP19A1SERPINA6SHBGMMP2 | |
| SCHEMBL10975419 | 0.81 | — | — | |
| SCHEMBL21678057 | 0.78 | TLR4 (0.34) | TLR4CYP19A1 | |
| SCHEMBL440413 | 0.77 | CYP19A1 (0.35) | TLR4CYP19A1SERPINA6SHBGMMP2 | |
| SCHEMBL19257857 | 0.74 | CYP2C19 (0.40) | CYP19A1SERPINA6SHBGMMP2SLC22A1 | |
| SCHEMBL296381 | 0.74 | TLR4 (0.35) | TLR4CYP19A1 | |
| SCHEMBL5684775 | 0.74 | TLR4 (0.47) | TLR4CYP19A1SHBGALDH1A1AR | |
| SCHEMBL18175548 | 0.74 | CYP2C19 (0.40) | CYP19A1SERPINA6SHBGMMP2SLC22A1 | |
| SCHEMBL10972979 | 0.72 | HTR1A (0.44) | — | |
| SCHEMBL11181948 | 0.71 | TLR4 (0.47) | TLR4CYP19A1SHBGMMP2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8465674-B2 | Decahydronaphthalene compound, liquid crystal composition including the compound and liquid crystal display device containing the liquid crystal composition | JNC CORPORATION (JP) | 2013-06-18 | — | — | US | disclosed |
| US-20120145959-A1 | DECAHYDRONAPHTHALENE COMPOUND, LIQUID CRYSTAL COMPOSITION INCLUDING THE COMPOUND AND LIQUID CRYSTAL DISPLAY DEVICE CONTAINING THE LIQUID CRYSTAL COMPOSITION | JNC PETROCHEMICAL CORPORATION (JP) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120145959-A1 | DECAHYDRONAPHTHALENE COMPOUND, LIQUID CRYSTAL COMPOSITION INCLUDING THE COMPOUND AND LIQUID CRYSTAL DISPLAY DEVICE CONTAINING THE LIQUID CRYSTAL COMPOSITION | DCUN1D2, OCIAD1, CPNE4 | TLR4 4459/4885CYP19A1 1181/4885SERPINA6 4500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.